Massive Bio is looking to create the world’s largest AI-enabled ‘just-in-time’ oncology site network to accelerate study recruitment – and believes that 15-20% of advanced-stage cancer patients can be enrolled in clinical trials, says CEO. Massive Bio is an advisory services company, providing artificial intelligence (AI) enabled clinical trial matching and other services to contract research originations (CROs) and pharmaceutical companies.
Massive Bio is an advisory services company, providing artificial intelligence (AI) enabled clinical trial matching and other services to contract research originations (CROs) and pharmaceutical companies.
The NY-based company recently launched a global partnership network, or ‘Hub,’ through which it aims to build the world’s largest AI-enabled just-in-time (JIT) precision oncology clinical trial network.
